Lars Mecklenburg, DVM, PhD, DACVP, FIATP
Site Lead, Labcorp Early Development Services GmbH, Muenster, Germany
Lars Mecklenburg is Site Lead of Labcorp Early Development Services GmbH, as of June 2019, and is an Executive Director in the global Safety Assessment team of Labcorp Early Development.
Prior to joining Labcorp in April, 2014, Lars was Vice President of Global Preclinical Product Development at Fresenius Kabi, a global health company that offers medications and medical devices for infusion, transfusion and clinical nutrition.
Previously, he served as the Vice President for Clinical Operations at Indivumed, a global oncology company, and as Head of Preclinical Product Development and Pathology at Nycomed, a Swiss pharmaceutical company that was acquired by Takeda Pharmaceuticals in September 2011.
In these roles, Lars Mecklenburg contributed to the preclinical development of a large number of medicinal products and medical devices from a broad variety of product classes and in all stages of development, ranging from lead optimization to life-cycle management.
Lars Mecklenburg studied veterinary sciences at the School of Veterinary Medicine in Hannover, Germany. He specialized in pathology as a Diplomate of the American College of Veterinary Pathologists and served as faculty in pathobiology at Texas A&M university. He is a Fellow of the International Academy of Toxicologic Pathology and completed the European Toxicology Risk Assessment Training Programme TRISK, that was co-financed by the European Commission in 2009.